<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842542</url>
  </required_header>
  <id_info>
    <org_study_id>44-03014-000</org_study_id>
    <nct_id>NCT01842542</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset</brief_title>
  <official_title>An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuronetics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuronetics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of acute NeuroStar TMS
      therapy in women who have postpartum depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in
      patients with MDD with postpartum onset.

      Determine the safety of NeuroStar TMS Therapy by assessment of any medically significant,
      device-related adverse events during acute treatment.

      Determine the Safety of NeuroStar TMS Therapy by assessment of maternal and infant
      interactions on standardized bonding questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the antidepressant effectiveness of acute treatment with NeuroStar TMS Therapy in patients with MDD with postpartum onset</measure>
    <time_frame>up to 8 weeks.</time_frame>
    <description>Acute NeuroStar TMS treatment of 5 days per week for upto 8 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of NeuroStar TMS Therapy.</measure>
    <time_frame>upto 8 weeks plus 3 week taper.</time_frame>
    <description>Medically significant, device related adverse events will be collected during the acute and taper phase.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine the safety of NeuroStar TMS Therapy by assessment of maternal and infant interactions on standardized bonding questionnaires.</measure>
    <time_frame>Up to 8 weeks plus 3 week taper.</time_frame>
    <description>Patients complete questionnaires during the acute and taper treatment phase at protocol specific timepoints.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Depression, Postpartum</condition>
  <arm_group>
    <arm_group_label>Transcranial Magnetic Stimulation (TMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.
Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroStar Transcranial Magnetic Stimulation (TMS)</intervention_name>
    <description>Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.
3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician.</description>
    <arm_group_label>Transcranial Magnetic Stimulation (TMS)</arm_group_label>
    <other_name>NeuroStar TMS Therapy Treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female outpatients, 18 to 50 years of age.

          -  Diagnosis of DSM-IV defined Major Depressive Disorder, single or recurrent episode,
             with current episode duration of at least 2 weeks.

          -  Onset and duration of current illness within 6 months of live childbirth.

          -  HAMD17 total score of greater than or equal to 18 and a score on the Edinburgh
             Postnatal Depression scale (EPDS) greater than or equal to 10.

          -  Patient cannot be on an antidepressant or other psychotropic medications during the
             study.

          -  Capable and willing to provide informed consent.

          -  Signed HIPAA authorization.

          -  Able to adhere to the treatment schedule.

        Exclusion Criteria:

          -  Individuals diagnosed by the Investigator with the following conditions (current
             unless otherwise stated): Depression secondary to a general medical condition, or
             substance-induced Seasonal pattern of depression as defined by DSM-IV;History of
             substance abuse or dependence within the past year(except nicotine and caffeine);Any
             psychotic disorder (lifetime), including schizoaffective disorder, or major depression
             with psychotic features in this or previous episodes;Bipolar disorder;Eating disorder
             (current or within the past year);Obsessive compulsive disorder (lifetime); or
             Post-traumatic stress disorder (current or within the past year).

          -  Individuals with a clinically defined neurological disorder or insult including, but
             not limited to:Any condition likely to be associated with increased intracranial
             pressure;Space occupying brain lesion;History of cerebrovascular accident;Transient
             ischemic attack within two years; Cerebral aneurysm; Dementia;Parkinson's
             disease;Huntington's chorea;Multiple sclerosis.

          -  History of treatment with Vagus Nerve Stimulation.

          -  History of failure to respond to an adequate course of ECT treatment.

          -  Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable
             cardiac disease.

          -  Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or
             electrodes) or any other metal object within or near the head, excluding the mouth,
             that cannot be safely removed.

          -  Women of child-bearing potential not using a medically accepted form of contraception
             when engaging in sexual intercourse.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Brock, MD</last_name>
    <role>Study Director</role>
    <affiliation>Neuronetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hartford Hospital Institute of Living</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Adult Psychiatry - Springhill</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harmonex Neuroscience and Research of Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrative Psychiatry</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMS Medical Associates of NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMS Center of Lehigh Valley</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah - Neuropsychiatric Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum Depression, NeuroStar TMS Therapy, TMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depression, Postpartum</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

